Carfilzomib (PR-171)

For research use only.

Catalog No.S2853

132 publications

Carfilzomib (PR-171) Chemical Structure

CAS No. 868540-17-4

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. Carfilzomib activates prosurvival autophagy and induces cell apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 476 In stock
USD 170 In stock
USD 270 In stock
USD 670 In stock
USD 870 In stock
USD 1170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Carfilzomib (PR-171) has been cited by 132 publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. Carfilzomib activates prosurvival autophagy and induces cell apoptosis.
Targets
Proteasome [1]
(ANBL-6 cells)
5 nM
In vitro

Carfilzomib inhibits proliferation in a variety of cell lines and patient-derived neoplastic cells, including multiple myeloma, and induced intrinsic and extrinsic apoptotic signaling pathways and activation of c-Jun-N-terminal kinase (JNK). Carfilzomib reveals enhanced anti-MM activity compared with bortezomib, overcome resistance to bortezomib and other agents, and acts synergistically with dexamethasone (Dex). Carfilzomib shoes preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, with over 80% inhibition at doses of 10 nM. Short exposure to low-dose Carfilzomib leads to preferential binding specificity for the β5 constitutive 20S proteasome and the β5i immunoproteasome subunits. Measurement of caspase activity in ANBL-6 cells pulsed with Carfilzomib reveals substantial increases in caspase-8, caspase-9, and caspase-3 activity after 8 hours, giving a 3.2-, 3.9- and 6.9-fold increase, respectively, over control cells after 8 hours. In carfilzomib pulse-treated cells, the mitochondrial membrane integrity is decreased to 41% (Q1 + Q2), compared with 75% in vehicle-treated control cells. [1] In another study, Carfilzomib has also shown preclinical effectiveness against hematological and solid malignancies. [2] Carfilzomib directly inhibits osteoclasts formation and bone resorption. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MM.1S NXXRO5hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjSNE0yODBibl2= Mof3OFghcA>? NXn0NG5ZUUN3MNMgQeKhOTBibl2= M3HHXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{GyOVQ{Lz5{NUOxNlU1OzxxYU6=
NCI-H929  MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjXS5FYOC1zMECgcm0> NIfYbGU1QCCq MoTSTWM2OCB;wrCxOEBvVQ>? M2jSVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{GyOVQ{Lz5{NUOxNlU1OzxxYU6=
SUDHL16  NH6xOo1CeG:ydH;zbZMhSXO|c3H5 M{m4TFIvPeLCk{OuOUBvVQ>? M2jpXlQ5KGh? MXvlcohidmOnczD0bIUh[2WubDDk[YF1cCClbz30doVifG2nboSge4l1cCCDQ2mxNlE2 M2L0XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkO5PVM2Lz5{NUKzPVk{PTxxYU6=
SUDHL14 MV7BdI9xfG:|aYOgRZN{e2G7 M2jVUlIvPeLCk{OuOUBvVQ>? NXTC[JBrPDhiaB?= NFHIfmJmdmijbnPld{B1cGViY3XscEBl\WG2aDDjc{11emWjdH3lcpQhf2m2aDDBR3kyOjF3 MnnuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{M{m5N|UoRjJ3MkO5PVM2RC:jPh?=
U2932 Ml22RZBweHSxc3nzJGF{e3OjeR?= MV[yMlXjiJN|LkWgcm0> NIrQUYc1QCCq NV[0[Ypw\W6qYX7j[ZMhfGinIHPlcIwh\GWjdHigZ48ufHKnYYTt[Y51KHerdHigRWN[OTJzNR?= M3XRfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkO5PVM2Lz5{NUKzPVk{PTxxYU6=
P-UMSCC-1 NEX4e25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFzLkKgcm0> NUG0V4RsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUxOzlpPkK0PVE2ODN7PD;hQi=>
R-UMSCC-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmroTWM2OD1{Mkm0JI5O MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUCzPUc,OjR7MUWwN|k9N2F-
P-Cal33 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHubVl6UUN3ME2xO{4{KG6P MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUCzPUc,OjR7MUWwN|k9N2F-
R-Cal33 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1GxNWlEPTB;MUGxNkBvVQ>? M1vBclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NFM6Lz5{NEmxOVA{QTxxYU6=
Jurkat MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3W[YUyNTFzbl2= MVe0PEBp M362eYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSvZX70JJdqfGhidn;ybY5we3SjdB?= M17wUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OECxNVI5Lz5{NEiwNVEzQDxxYU6=
Jurkat MkjORZBweHSxc3nzJGF{e3OjeR?= NHHpXWI5KG6P NX3wW2o5OjRxNEigbC=> MmizbY5lfWOnczDhdI9xfG:|aYOsJINie3Cjc3WgZYN1cX[jdHnvckwh[W6mIGDBVnAh[2ynYY\h[4Uh[29vdILlZZRu\W62IIfpeIghfm:{aX7vd5RifA>? M2XUSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OECxNVI5Lz5{NEiwNVEzQDxxYU6=
UMSCC-22A MV;BdI9xfG:|aYOgRZN{e2G7 NFXFU40zODBibl2= NILONoYzPCCq M3HtWolv\HWlZTD0bIUh[2WubDDhdI9xfG:|aYOgZ48ufHKnYYTt[Y51KHerdHigU25ZKDB7MUK= NEOyXlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmyPVgxOyd-MkK5Nlk5ODN:L3G+
UMSCC-22B MWfBdI9xfG:|aYOgRZN{e2G7 MkPNNlAxKG6P NYL2ZnBzOjRiaB?= MnvMbY5lfWOnIITo[UBk\WyuIHHwc5B1d3OrczDjc{11emWjdH3lcpQhf2m2aDDPUnghODlzMh?= NHvEcm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmyPVgxOyd-MkK5Nlk5ODN:L3G+
1483 NYHFSWpsSXCxcITvd4l{KEG|c4PhfS=> NILxS2MzODBibl2= M3LjN|I1KGh? M{X4S4lv\HWlZTD0bIUh[2WubDDhdI9xfG:|aYOgZ48ufHKnYYTt[Y51KHerdHigU25ZKDB7MUK= NFfORW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmyPVgxOyd-MkK5Nlk5ODN:L3G+
UMSCC-1 M3y1eWFxd3C2b4Ppd{BCe3O|YYm= MmLCNlAxKG6P NF\6V5UzPCCq NF\SfoxqdmS3Y3WgeIhmKGOnbHygZZBweHSxc3nzJINwNXS{ZXH0cYVvfCC5aYToJG9PYCByOUGy Mnq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7Mkm4NFMoRjJ{OUK5PFA{RC:jPh?=
UMSCC-22A M2[xVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfjTWM2OD1|OD63JOKyKDFwMDDuUS=> NXm3To13RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5Nlk5ODNpPkKyPVI6QDB|PD;hQi=>
UMSCC-22B MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fBNmlEPTB;M{CuO{DDuSB7LkOgcm0> MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl{OUiwN{c,OjJ7Mkm4NFM9N2F-
1483 MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTVyLkWgxtEhOTFwOTDuUS=> NYD4O4NERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5Nlk5ODNpPkKyPVI6QDB|PD;hQi=>
UMSCC-1 NEnkPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS1TWM2OD1|ND62JOKyKDJwNjDuUS=> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl{OUiwN{c,OjJ7Mkm4NFM9N2F-
Cal33 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPPS2RKSzVyPUS5MlMhyrFiOD65JI5O NGf0THE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmyPVgxOyd-MkK5Nlk5ODN:L3G+
PCI-15A MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTdyLkSgxtEhOjJwNjDuUS=> M1XYTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUK5PFA{Lz5{MkmyPVgxOzxxYU6=
PCI-15B NWDTWVRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrvWItKSzVyPUO5MlUhyrFiMUGuNEBvVQ>? M{fCTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUK5PFA{Lz5{MkmyPVgxOzxxYU6=
OSC-19 NIXaeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofvTWM2OD1zOD6zJOKyKDRwMjDuUS=> NFr5XmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmyPVgxOyd-MkK5Nlk5ODN:L3G+
SUDHL16 MWDBdI9xfG:|aYOgRZN{e2G7 MWSyMlAuPC5yIH7N M{S1NlQ5KGh? MmrGbY5lfWOnczDj[YxtKGSnYYToJINwNXS{ZXH0cYVvfCC5aYToJI9j[XSxY3zhfC=> Mlr2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2MUG4PVkoRjJ{NEGxPFk6RC:jPh?=
SUDHL16 M2PreWZ2dmO2aX;uJGF{e2G7 NUPXVZk{Oi53IH7N NITiUoMzPCCq M3zueoFkfGm4YYTld{BLVktuIHnuZYN1cX[jdHXzJGFMXCxidYCtdoVofWyjdHXzJG5wgGFuIHHu[EBqdmS3Y3XzJO6{UDKDLmigZ48ufHKnYYTt[Y51KHerdHigc4JifG:lbHH4 M4XQPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEGxPFk6Lz5{MkSxNVg6QTxxYU6=
Granta NYjJ[2dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq4SnJwOC12IH7N NU\Rd5ozPDhiaB?= Mn\obY5lfWOnIHPlcIwh\GWjdHigZ48ufHKnYYTt[Y51KHerdHigTGFFS0m| MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd3MEKyOEc,OjF5NUCyNlQ9N2F-
SUDHL16 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWxMVQhdk1? NUP5NZVjOzZiaB?= MVnpcoR2[2ViY3XscEBl\WG2aDDjc{11emWjdH3lcpQhf2m2aDDIRWREUXN? NUPHRYprRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyN|M6PzNpPkKwNlM{QTd|PD;hQi=>
MOLT4 M3jQVGZ2dmO2aX;uJIF{e2G7 NUm2VHhCOSCqch?= NWjDS2J[UW6qaXLpeIlwdiCxZjDjbJlud3S{eYDzbY4udGmtZTDhZ5Rqfmm2eTDv[kAzOFNicILveIVie2:vZTDpckBpfW2jbjDNU2xVPCClZXzsd{Bi\nSncjCxJIhzKGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiYYPzZZktKEmFNUCgQUAxNjByNUGg{txONg>? NYKyOoN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzOFg1PzNpPkG5N|Q5PDd|PD;hQi=>
MESSA M{nCSGN6fG:2b4jpZ4l1gSCjc4PhfS=> M3jvV|czKGi{cx?= MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSXNUSSClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwdDDhd5NigSxiSVO1NEA:KDBwMEG4JO69VS5? M1LM[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{S4OFc{Lz5zOUO0PFQ4OzxxYU6=
MESSA NGLDW3BEgXSxdH;4bYNqfHliYYPzZZk> M1GwdFczKGi{cx?= MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBufWy2aXTyeYchemW|aYP0ZY5k\SC2cnHud5BwenSncjDlfJBz\XO|aX7nJIRwgG:{dXLpZ4lvKHKnc3nzeIFvfCCqdX3hckBOTVOVQTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDseY1qdmW|Y3XueEBie3OjeTygTWM2OCB;IECuOFE{KM7:TT6= M3nKXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{S4OFc{Lz5zOUO0PFQ4OzxxYU6=
RPMI8226 MYjDfZRwfG:6aXPpeJkh[XO|YYm= NUjtephxPzJiaILz Mm\OR5l1d3SxeHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmDNTVgzOjZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvODF|MUmg{txONg>? NGjKXHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe2O|gyQCd-MkS3Olc5OTh:L3G+
NCI-H929 NX\ET2x2S3m2b4TvfIlkcXS7IHHzd4F6 M2fiO|czKGi{cx?= NVm3dZo3S3m2b4TvfIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUh7MkmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMEKxN|Ih|ryPLh?= NULOPXJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3Olc5OThpPkK0O|Y4QDF6PD;hQi=>
CCRF-CEM MlXURY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? Mmf6O|IhcHK| MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOFUl[tR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDvfJltfWOrZnXybY4hdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC5yME[xJO69VS5? NYTrPGR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yN|EyPjJpPkK2NlMyOTZ{PD;hQi=>
RPMI8266 NUS1RnlVSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MYG3NkBpenN? M3:5TmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmDNTVgzPjZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JI95gWy3Y3nm[ZJqdiCudX3pcoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkCxN|kh|ryPLh?= NH71OVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzNVE3Oid-Mk[yN|EyPjJ:L3G+
HCT116 MlyyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MlS5O|IhcHK| MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nlib4j5cJVkcW[ncnnuJIx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODF7MzFOwG0v NHfuWZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzNVE3Oid-Mk[yN|EyPjJ:L3G+
A431 M3PWTWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MYm3NkBpenN? NWDLOXBzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDvfJltfWOrZnXybY4hdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC5yMkO4JO69VS5? MoL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{M{GxOlIoRjJ4MkOxNVYzRC:jPh?=
TOV21G MmTZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NHvKdoU4OiCqcoO= NYHuXoJYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDUU3YzOUdiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JI95gWy3Y3nm[ZJqdiCudX3pcoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkCyN|gh|ryPLh?= M{T6OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkOxNVYzLz5{NkKzNVE3OjxxYU6=
RKO MVPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M2T2UFczKGi{cx?= MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKNTzDj[YxteyCjZoTldkA4OiCqcoOgZpkhd3i7bIXjbYZmemmwIHz1cYlv\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNFI4OSEQvF2u MnvUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{M{GxOlIoRjJ4MkOxNVYzRC:jPh?=
MM1S M1LCcGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MUO3NkBpenN? MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2PMWOgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMECxOUDPxE1w M{XnVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{[1OFA5Lz5{N{e2OVQxQDxxYU6=
RPMI8226 MnTzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NIW4WFg4OiCqcoO= M3PtPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmDNTVgzOjZiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgO|IhcHK|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvODF|MjFOwG0v M{\uN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{[1OFA5Lz5{N{e2OVQxQDxxYU6=
LCL NXXPZ3ppS3m2b4TvfIlkcXS7IHHzd4F6 MkHDOFghcHK| MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMR2wh[2WubIOgbIFz[m:{aX7nJJdqdGRidInw[UBxPTNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTC3RWFFNXO2YXnubY5oKGKjc3XkJGZCS1NiYX7hcJl{cXNuIFzEOVAhRSByLkCzJO69VS5? NVHITFlQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzRpPkK3PVk1PzN2PD;hQi=>
RD-ES NXj6[ohmS3m2b4TvfIlkcXS7IHHzd4F6 MmflOFghcHK| NX75PIQ4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWkRvRWOgZ4VtdHNiaHHyZo9zcW6pIIC1N{BufXSjboSgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUA4SUGGLYP0ZYlvcW6pIHLhd4VlKE[DQ2OgZY5idHm|aYOsJGxFPTBiPTCwMlA1OyEQvF2u NInEbHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{PCd-Mke5PVQ4OzR:L3G+
U266 MYrDfZRwfG:6aXPpeJkh[XO|YYm= M3iyOlQ5KGi{cx?= NEXHcI5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOjZ4IHPlcIx{KGijcnLvdolv\yCvdYThcpQheDV|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgO2FCTC2|dHHpcolv\yCkYYPl[EBHSUOVIHHuZYx6e2m|LDDMSFUxKD1iMD6wOkDPxE1w MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOEc,Ojd7OUS3N|Q9N2F-
WE68 MofUR5l1d3SxeHnjbZR6KGG|c3H5 M3fLRlQ5KGi{cx?= M3WweWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHdGPjhiY3XscJMhcGG{Yn;ybY5oKHerbHSgeJlx\SCyNUOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUA4SUGGLYP0ZYlvcW6pIHLhd4VlKE[DQ2OgZY5idHm|aYOsJGxFPTBiPTCwMlA5KM7:TT6= M37CNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|M1Lz5{N{m5OFc{PDxxYU6=
IMR90 Mm\VR5l1d3SxeHnjbZR6KGG|c3H5 MV60PEBpenN? M{e2NGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGlOWjlyIHPlcIx{KGijcnLvdolv\yC5aXzkJJR6eGVicEWzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhP0GDRD3zeIFqdmmwZzDiZZNm\CCIQVPTJIFv[Wy7c3nzMEBNTDVyIE2gNE4yOyEQvF2u M1nncFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|M1Lz5{N{m5OFc{PDxxYU6=
MCF10A MlLOR5l1d3SxeHnjbZR6KGG|c3H5 NGe1coQ1QCCqcoO= NHLzelhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0ZzMFGgZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDwOVMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSB5QVHEMZN1[WmwaX7nJIJie2WmIF\BR3Mh[W6jbInzbZMtKEyGNUCgQUAxNjN{IN88UU4> NWi4RYN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzRpPkK3PVk1PzN2PD;hQi=>
SKOV3 M1PVbGN6fG:2b4jpZ4l1gSCjc4PhfS=> MlTMOFghcHK| MWHDfZRwfG:6aXPpeJkh[WejaX7zeEBxPTNiZHXmbYNq\W62IHj1cYFvKFONT2[zJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgO2FCTC2|dHHpcolv\yCkYYPl[EBHSUOVIHHuZYx6e2m|LDDMSFUxKD1iMD6zNkDPxE1w MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOEc,Ojd7OUS3N|Q9N2F-
MDA-MB-468 M171PWN6fG:2b4jpZ4l1gSCjc4PhfS=> NWDI[4RKPDhiaILz NVHKZ3JVS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{Bp[XKkb4LpcochdXW2YX70JJA2OyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IEfBRWQue3SjaX7pcoch[mG|ZXSgSmFEWyCjbnHsfZNqeyxiTFS1NEA:KDBwM{Og{txONg>? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOEc,Ojd7OUS3N|Q9N2F-
HNDF NHSzcY5EgXSxdH;4bYNqfHliYYPzZZk> MmDkOFghcHK| MmXSR5l1d3SxeHnjbZR6KGGpYXnud5QhUE6GRjDj[YxteyCqYYLic5Jqdmdid3ns[EB1gXCnIIC1N{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KDeDQVStd5RicW6rbnegZoF{\WRiRlHDV{BidmGueYPpd{whVER3MDC9JFAvOzVizszNMi=> NFTKWZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{PCd-Mke5PVQ4OzR:L3G+
KGN NYLx[FZjS3m2b4TvfIlkcXS7IHHzd4F6 NIKyVVM1QCCqcoO= MlfLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2dPKGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUheDV|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgO2FCTC2|dHHpcolv\yCkYYPl[EBHSUOVIHHuZYx6e2m|LDDMSFUxKD1iMD60OUDPxE1w M4HkZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|M1Lz5{N{m5OFc{PDxxYU6=
MCF7 NYe5b3NuS3m2b4TvfIlkcXS7IHHzd4F6 MWS0PEBpenN? M{TDPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMhcGG{Yn;ybY5oKHerbHSgeJlx\SCyNUOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUA4SUGGLYP0ZYlvcW6pIHLhd4VlKE[DQ2OgZY5idHm|aYOsJGxFPTBiPTC0MlUh|ryPLh?= NVrmbHRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzRpPkK3PVk1PzN2PD;hQi=>
MCF7 NWj3OWNxTnWwY4Tpc44h[XO|YYm= NGLTTHk{PSCwTR?= NIHK[mM1KGi{cx?= MVnJcohq[mm2aX;uJI9nKDJ4UzDwdo91\WG|b33lJIlvKGi3bXHuJG1ETjdiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKGirZ3igcY9t\WO3bHHyJJdmcWeqdDDwc4x6fWKrcYXpeIlvNWOxbnr1[4F1\WRicILveIVqdnNiYYSgN|Uhdk1iYX\0[ZIhPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MkLKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N|QoRjJ5OUm0O|M1RC:jPh?=
MDA-MB-468 M2jiVWZ2dmO2aX;uJIF{e2G7 Ml:0N|Uhdk1? MoS3OEBpenN? M1TOSGlvcGmkaYTpc44hd2ZiMk\TJJBzd3SnYYPvcYUhcW5iaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4YhcGmpaDDtc4xm[3WuYYKge4Vq\2i2IIDvcJl2[mmzdXn0bY4u[2:waoXnZZRm\CCycn;0[YlveyCjdDCzOUBvVSCjZoTldkA1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? M{PCfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|M1Lz5{N{m5OFc{PDxxYU6=
MM1S M4DrW2N6fG:2b4jpZ4l1gSCjc4PhfS=> NVe0O456PzJiaILz Mly0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUW0yWyClZXzsd{Bu\WG|dYLl[EBi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5MEBKSzVyIE2gNE4xODF3IN88UU4> NWrYT2d5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwNlc2OzFpPkK4NFI4PTNzPD;hQi=>
RPMI8226 MkDFR5l1d3SxeHnjbZR6KGG|c3H5 M2WzWFczKGi{cx?= NHG5Uo9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTWE2LOEKyOkBk\WyuczDt[YF{fXKnZDDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR|UxKD1iMD6wNVMzKM7:TT6= Mk\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyMke1N|EoRjJ6MEK3OVMyRC:jPh?=
TC32 NXG0SFJNeUiWUzDhd5NigQ>? M1e3XJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy| M4jRflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS MXjxTHRUKGG|c3H5 MV3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy| M4jaNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 NVPJcGpMeUiWUzDhd5NigQ>? NVr6VJBUeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= M2rIRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY NWOwd3BHeUiWUzDhd5NigQ>? MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? MmDKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 NHrDWWdyUFSVIHHzd4F6 MkPjdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= NHHrTIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 NHX2W3NyUFSVIHHzd4F6 MYHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? M2TzOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD MnSzdWhVWyCjc4PhfS=> MnGwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ NXjiWnJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH NIS3OmRyUFSVIHHzd4F6 M1PBOJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz MmizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 MV7xTHRUKGG|c3H5 M2izfZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) M2PhNpFJXFNiYYPzZZk> NFewTlFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO= NWW4[2lYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 NUHlfIszeUiWUzDhd5NigQ>? M{\XSZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= MmizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 MmrjdWhVWyCjc4PhfS=> NYGxZ|NteUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-12 Mm\ZdWhVWyCjc4PhfS=> MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0yOiClZXzsdy=> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 MlPTdWhVWyCjc4PhfS=> NWrpcoM6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? MmXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
fibroblast cells MWjxTHRUKGG|c3H5 MoLqdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKGOxboTyc4whUGhid3ns[EB1gXCnIH\pZpJw[myjc4SgZ4VtdHN? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB-EBc1 MUXxTHRUKGG|c3H5 NIDRU3VyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSi2HQnOxJINmdGy| M{nZeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH MlzJdWhVWyCjc4PhfS=> NI[3d4JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy| M1;MO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 MmjmdWhVWyCjc4PhfS=> NXexSVJieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= M17JTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 NIXUVmlyUFSVIHHzd4F6 NHfVR25yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd|IHPlcIx{MQ>? NWHQZZZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30 NX;UN2h1eUiWUzDhd5NigQ>? MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh|MDDj[Yxtew>? NFi0VmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 MnLVdWhVWyCjc4PhfS=> NGS5XlFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1|NzDj[Yxtew>? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) MoXYdWhVWyCjc4PhfS=> M1zUeZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG1IKDZ|IDi2MXRIKFJrIHPlcIx{ M3judVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30 MmPjdWhVWyCjc4PhfS=> MmnzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=> MmrKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
fibroblast cells MYHxTHRUKGG|c3H5 MnrOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgZ49vfHKxbDDIbEB4cWymIIT5dIUh\mmkcn;icIF{fCClZXzsdy=> M4jTWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 NXfvSVF2eUiWUzDhd5NigQ>? Mn;FdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgU2hUNTVyIHPlcIx{ NV6ydnZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH MXzxTHRUKGG|c3H5 NFOxPVFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= M4\QOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Daoy MnT6dWhVWyCjc4PhfS=> NEm0[4VyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKESjb4mgZ4VtdHN? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 M4e3[ZFJXFNiYYPzZZk> MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGIHPhd5Bie2Vic3Py[YVvKG[xcjDUR|MzKGOnbHzz MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 NHXIXYRyUFSVIHHzd4F6 MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> M1XmclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) NFS0OJNyUFSVIHHzd4F6 M2nKfpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1Sgeoli[mmuaYT5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? NYO0VVlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 MV3xTHRUKGG|c3H5 MVnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= NFTEfVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC NWnJc3d[eUiWUzDhd5NigQ>? NILw[3lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NUmwW5dmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 M1;ZUpFJXFNiYYPzZZk> NEfzblJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=> MlHBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 MlfNdWhVWyCjc4PhfS=> MVnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? M{LCUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 NF7kfoRyUFSVIHHzd4F6 MlL6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? M2OwUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC MnrZdWhVWyCjc4PhfS=> NIXhZXVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy| NFj1eoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 MUXxTHRUKGG|c3H5 NXXTWldMeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= MofrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
TC32 MUjxTHRUKGG|c3H5 NFXIXZpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{ NEP3[3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 Mnv0dWhVWyCjc4PhfS=> M3nXdJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOThiY3XscJM> NWrS[Wd7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 NYO1fm4zeUiWUzDhd5NigQ>? MlHtdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV4Fwey1{IHPlcIx{ NEnuVIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 NYDzfZFWeUiWUzDhd5NigQ>? NHHjWVJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= NVy2UGg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD MoTydWhVWyCjc4PhfS=> MW\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHJFKGOnbHzz NEnmRXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
ANBL-6 M373T2Z2dmO2aX;uJIF{e2G7 MlTPTY5pcWKrdHnvckBw\iB{MGOgdJJwfGWjc3;t[UBi[3Srdnn0fUBqdiCqdX3hckBCVkKOLU[gZ4VtdHNuIFnDOVAhRSByLkCxJO69VS5? NVnOfYsxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2OVIyPDNpPkK5OlUzOTR|PD;hQi=>
MCF7 M2CwdGN6fG:2b4jpZ4l1gSCjc4PhfS=> MY[0PEBpenN? NXjD[lA4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yMESxJO69VS5? M3uz[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMU[1N|Q1Lz5|MEG2OVM1PDxxYU6=
MDA-MB-231 MoXqR5l1d3SxeHnjbZR6KGG|c3H5 MoHpOFghcHK| M2e2bGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFA1PCEQvF2u MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF4NUO0OEc,OzBzNkWzOFQ9N2F-
RPMI8226 M373VGN6fG:2b4jpZ4l1gSCjc4PhfS=> MlLrOFghcHK| M4HLdmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJRVUl6MkK2JINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCwOlch|ryPLh?= M2DPTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMU[1N|Q1Lz5|MEG2OVM1PDxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pERK / ERK / pSTAT5 / STAT5 / pPI3K / PI3K; 

PubMed: 24590311     


Western blot analysis for activated (phosphorylated) ERK, Stat5 and PI3K signaling pathways following exposure to carfilzomib, total levels of ERK, Stat5 and PI3K were used as a loading control.

caspase-9 / caspase-8; 

PubMed: 24590311     


Western blot analysis for activated (cleaved) caspase-8 and caspase-9 following exposure to carfilzomib.

c-PARP / PARP / caspase-3; 

PubMed: 22929803     


UMSCC-22A, UMSCC-22B, 1483 and UMSCC-1 cells were treated for 24 hours with 0.1% DMSO, or 200 nmol/L carfilzomib or ONX 0912, followed by immunoblotting with anti-PARP, anti-caspase-3, or anti-β-actin. Shown are full-length PARP, cleaved PARP (c-PARP), and the cleaved, active subunits of caspase-3. Similar results were obtained in 3 independent experiments.

Bcl-2 / Bcl-Xl / Mcl-1 / Bik / Bim / Bax / Bak; 

PubMed: 22929803     


UMSCC-22A, UMSCC-22B, 1483 and UMSCC-1 cells were treated for 24 hours with 0.1% DMSO, or 100 nmol/L carfilzomib or ONX 0912, followed by immunoblotting for the indicated proteins. In the case of Bik immunoblotting, cells were treated with 200 nmol/L carfilzomib or ONX 0912 to more clearly demonstrate Bik upregulation in 1483 and UMSCC-1 cells. Blots shown are representative of 3 independent experiments. 

Atg5 / Atg12 / Beclin-1 / LC3-II; 

PubMed: 22929803     


HNSCC cells were treated for 24 hours with 100 nmol/L carfilzomib or ONX 0912, or with 0.1% DMSO. Immunoblots were probed for Beclin-1, Atg5/12 conjugate, LC3-II, or β-actin. Representative blots from 3 independent experiments are shown. 

Noxa / Bik / Puma / Mcl-1; 

PubMed: 25548100     


SW620 cells were treated with the indicated dosage for 48 h. Expression of Noxa, Bik and/or Puma, c-myc and Mcl-1 proteins was then analyzed by immunoblotting. Tubulin served as control for protein loading. 

EGFR / HER2 / ER alpha / p-Akt(Ser473) / Akt / p-ERK / ERK / p53; 

PubMed: 29069787     


T47D and MCF7 cells were cultured with the indicated carfilzomib concentrations for 32 or 36 hours, respectively. Western blots of protein lysates were probed with the indicated antibodies. β-actin served as loading control.

BDP1 / HER2(Tyr1248) / HER2(Tyr1221/Tyr1222) / PARP1 / caspase-7 / p53 Mut; 

PubMed: 29069787     


BT474 cells were cultured in the presence of the indicated carfilzomib concentrations for 32 hours. Western blots of protein lysates were probed with the indicated antibodies.

HLA class I; 

PubMed: 26323098     


Immunofluorescence analysis was performed to confirm the consequence that down-regulation of HLA class I was in a dose- and time-dependent manner.

24590311 22929803 25548100 29069787 26323098
Growth inhibition assay
Cell viability; 

PubMed: 27655642     


Cytotoxic effects of carfilzomib on breast cancer cells in MTT assays. Seven human breast cancer cell lines, MCF7, T-47D, MDA-MB-361, HCC1954, MDA-MB-468, MDA-MB-231, and BT-549 were treated with carfilzomib at 0, 0.001 μM, 0.01 μM, 0.05 μM, 0.1 μM, 1 μM, 10 μM, or 50 μM for 72 h, then subjected to MTT assays. The absorbance of each well was measured at 540 nm and plotted for the cell viability curve. IC50 values of carfilzomib in breast cancer cell lines were listed.

27655642
In vivo Carfilzomib moderately reduces tumor growth in an in vivo xenograft model. Carfilzomib effectively decreases multiple myeloma cell viability following continual or transient treatment mimicking. Carfilzomib increases trabecular bone volume, decreases bone resorption and enhances bone formation in non-tumor bearing mice. [3]

Protocol

Kinase Assay:[1]
- Collapse

Enzyme-linked immunosorbent assay for subunit profiling of carfilzomib:

ANBL-6 cells (2 × 106/well) are plated in 96-well plates and treated with Carfilzomib doses from 0.001 to 10 μM for 1 hour. Cells are then lysed (20 mM Tris-HCl, 0.5 mM EDTA), and cleared lysates are transferred to polymerase chain reaction (PCR) plates. A standard curve is generated using untreated ANBL-6 cell lysates starting at a concentration of 6 μg protein/μL. The active site probe [biotin-(CH2)4-Leu-Leu-Leu-epoxyketone; 20 μM] is added and incubated at room temperature for 1 hour. Cell lysates are then denatured by adding 1% sodium dodecyl sulfate (SDS) and heating to 100°C, followed by mixing with 20 μL per well streptavidin-sepharose high-performance beads in a 96-well multiscreen DV plate and incubated for 1 hour. These beads are then washed with enzyme-linked immunosorbent assay (ELISA) buffer (PBS, 1% bovine serum albumin, and 0.1% Tween-20), and incubated overnight at 4°C on a plate shaker with antibodies to proteasome subunits. Antibodies used included mouse monoclonal anti-β1, anti-β2, anti-β1i, and anti-β5i, goat polyclonal anti-β2i, and rabbit polyclonal anti-β5 (affinity-purified antiserum against KLH-CWIRVSSDNVADLHDKYS peptide). The beads are washed and incubated for 2 hours with horseradish peroxidase-conjugated secondary goat antirabbit, goat antimouse or rabbit antigoat antibodies. After washing, the beads are developed using the supersignal ELISA picochemiluminescence substrate. Luminescent detection is performed. Raw luminescence is converted to μg/mL by comparison with the standard curve and expressed as the % inhibition relative to vehicle control. Curve fits are generated using the following nonsigmoidal dose-response equation: Y = Bottom + (Top-Bottom)/(1 + 10̂((LogEC50 − X) × HillSlope)), where X is the logarithm of concentration, Y is the % inhibition, and EC50 is the dose showing 50% effect.
Cell Research:[1]
- Collapse
  • Cell lines: WST-1, ANBL-6 cells
  • Concentrations: 100 nM
  • Incubation Time: 1 hour
  • Method: WST-1 is used to determine the effects of proteasome inhibitor Carfilzomib on cell proliferation. The inhibition of proliferation is calculated in relation to parallel control cells that receives vehicle alone. A linear spline function is used to interpolate the median inhibitory concentration (IC50) using XLfit 4 software. The degree of resistance (DOR) is calculated using the formula: DOR = IC50(resistant cells)/IC50(sensitive cells). ANBL-6 cells pulsed with 100 nM carfilzomib are washed and suspended in PBS containing 5 μg/mL of JC-1, which exhibits potential-dependent accumulation in mitochondria. Analysis of the mitochondrial membrane potential-dependent color shift from 525 to 590 nm is carried out on a FacScan, and the data are analyzed with CellQuest software.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Beige-nude-XID mice
  • Dosages: 2.0 mg/kg
  • Administration: i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 50 mg/mL (69.45 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2%Tween 80+ddH2O
For best results, use promptly after mixing.
1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 719.91
Formula

C40H57N5O7

CAS No. 868540-17-4
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04407858 Recruiting -- Myeloma|Heart Failure|Hypertension European Georges Pompidou Hospital May 21 2020 --
NCT03673826 Recruiting Drug: Carfilzomib|Drug: Dexamethasone|Drug: Lenalidomide Smouldering Myeloma Stichting Hemato-Oncologie voor Volwassenen Nederland November 19 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How should I prepare solution of Carfilzomib for ongoing in vivo study?

  • Answer:

    This compound can be dissolved in 2% DMSO/30% PEG 300/dd H2O at 10 mg/ml as a suspension, and can be dissolved in 2% DMSO/ castor oil at 10 mg/ml as a clear solution.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Carfilzomib (PR-171) | Carfilzomib (PR-171) supplier | purchase Carfilzomib (PR-171) | Carfilzomib (PR-171) cost | Carfilzomib (PR-171) manufacturer | order Carfilzomib (PR-171) | Carfilzomib (PR-171) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID